Drug Dev Sector Surges on Strong Q2 Results | Business and Finance News

The drug development sector is on fire, with eight key companies smashing Q2 revenue targets by over four percent and showing bullish outlooks. Stocks are soaring—average gains of more than ten percent since earnings. Repligen led with 12% YoY growth, though its stock lagged peers. Azenta stunned with 12% revenue jump and an 8% beat, driving a 10% stock surge. IQVIA posted nearly 9% growth, exceeding forecasts by 1.5%, lifting shares 11%. Charles River Labs hit $990M in revenue, just missing YoY growth but still beating estimates by 2.5%, sending its stock up 19%. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/6c1a744988968d86